Sarcoidosis: an update on current pharmacotherapy options and future directions

References

• Baughman RP, Lower EE, du Bois RM. Sarcoidosis. Lancet (London, England). 2003;361(9363):1111–1118. DOI:10.1016/S0140-6736(03)12888-7
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Brito-Zerón P, Kostov B, et al. Google-driven search for big data in autoimmune geoepidemiology: analysis of 394,827 patients with systemic autoimmune diseases. Autoimmun Rev. 2015;14(8):670–679. DOI:10.1016/j.autrev.2015.03.008
   PubMed Web of Science ®Google Scholar
• Valeyre D, Prasse A, Nunes H, et al. Sarcoidosis. Lancet (London, England). 2014;383(9923):1155–1167. DOI:10.1016/S0140-6736(13)60680-7
   PubMed Web of Science ®Google Scholar
• Dubrey S, Shah S, Hardman T, et al. Sarcoidosis: the links between epidemiology and aetiology. Postgrad Med J. 2014;90(1068):582–589. DOI:10.1136/postgradmedj-2014-132584
   PubMed Web of Science ®Google Scholar
• McNicol MW, Luce PJ. Sarcoidosis in a racially mixed community. J R Coll Physicians Lond. 1985;19(3):179–183.
   PubMedGoogle Scholar
• Brito-Zerón P, Sellarés J, Bosch X, et al. Epidemiologic patterns of disease expression in sarcoidosis: age, gender and ethnicity-related differences. Clin Exp Rheumatol. 2016;34(3):380–388.
   PubMed Web of Science ®Google Scholar
• Henke CE, Henke G, Elveback LR, et al. The epidemiology of sarcoidosis in Rochester, Minnesota: a population-based study of incidence and survival. Am J Epidemiol. 1986;123(5):840–845.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Field S, Costabel U, et al. Sarcoidosis in America. Analysis based on health care use. Ann Am Thorac Soc. 2016;13(8):1244–1252. DOI:10.1513/AnnalsATS.201511-760OC
   PubMed Web of Science ®Google Scholar
• Dumas O, Abramovitz L, Wiley AS, et al. Epidemiology of sarcoidosis in a Prospective Cohort Study of U.S. women. Ann Am Thorac Soc. 2016;13(1):67–71. DOI:10.1513/AnnalsATS.201508-568BC
   PubMed Web of Science ®Google Scholar
• Fingerlin TE, Hamzeh N, Maier LA. Genetics of sarcoidosis. Clin Chest Med. 2015;36(4):569–584. DOI:10.1016/j.ccm.2015.08.002
   PubMed Web of Science ®Google Scholar
• Pereira CAC, Dornfeld MC, Baughman R, et al. Clinical phenotypes in sarcoidosis. Curr Opin Pulm Med. 2014;20(5):496–502. DOI:10.1097/MCP.0000000000000077
   PubMed Web of Science ®Google Scholar
• Rybicki BA, Iannuzzi MC. Epidemiology of sarcoidosis: recent advances and future prospects. Semin Respir Crit Care Med. 2007;28(1):22–35. DOI:10.1055/s-2007-970331
   PubMed Web of Science ®Google Scholar
• Wilsher ML. Seasonal clustering of sarcoidosis presenting with erythema nodosum. Eur Respir J. 1998;12(5):1197–1199.
   PubMed Web of Science ®Google Scholar
• Gerke AK, Tangh F, Yang M, et al. An analysis of seasonality of sarcoidosis in the United States veteran population: 2000-2007. Sarcoidosis Vasc Diffus lung Dis Off J WASOG /World Assoc Sarcoidosis Other Granulomatous Disord. 2012;29(2):155–158.
   PubMed Web of Science ®Google Scholar
• Barnard J, Rose C, Newman L, et al. Job and industry classifications associated with sarcoidosis in A Case-Control Etiologic Study of Sarcoidosis (ACCESS). J Occup Environ Med. 2005;47(3):226–234.
   PubMed Web of Science ®Google Scholar
• Jordan HT, Stellman SD, Prezant D, et al. Sarcoidosis diagnosed after September 11, 2001, among adults exposed to the World Trade Center disaster. J Occup Environ Med. 2011;53(9):966–974. DOI:10.1097/JOM.0b013e31822a3596
   PubMed Web of Science ®Google Scholar
• Li L, Silveira LJ, Hamzeh N, et al. Beryllium-induced lung disease exhibits expression profiles similar to sarcoidosis. Eur Respir J. 2016;47(6):1797–1808. DOI:10.1183/13993003.01469-2015
   PubMed Web of Science ®Google Scholar
• Newman LS. Metals that cause sarcoidosis. Semin Respir Infect. 1998;13(3):212–220.
   PubMedGoogle Scholar
• Paramothayan NS, Lasserson TJ, Jones PW. Corticosteroids for pulmonary sarcoidosis. Cochrane Database Syst Rev. 2005;2:CD001114. DOI:10.1002/14651858.CD001114.pub2
   Google Scholar
• Schutt AC, Bullington WM, Judson MA. Pharmacotherapy for pulmonary sarcoidosis: a Delphi consensus study. Respir Med. 2010;104(5):717–723. DOI:10.1016/j.rmed.2009.12.009
   PubMed Web of Science ®Google Scholar
• Gottlieb JE, Israel HL, Steiner RM, et al. Outcome in sarcoidosis. The relationship of relapse to corticosteroid therapy. Chest. 1997;111(3):623–631.
   PubMed Web of Science ®Google Scholar
• Rizzato G, Montemurro L, Colombo P. The late follow-up of chronic sarcoid patients previously treated with corticosteroids. Sarcoidosis Vasc Diffus lung Dis Off J WASOG /World Assoc Sarcoidosis Other Granulomatous Disord. 1998;15(1):52–58.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Judson MA, Teirstein A, et al. Presenting characteristics as predictors of duration of treatment in sarcoidosis. QJM. 2006;99(5):307–315. DOI:10.1093/qjmed/hcl038
   PubMed Web of Science ®Google Scholar
• Johns CJ, Michele TM. The clinical management of sarcoidosis. A 50-year experience at the Johns Hopkins Hospital. Medicine (Baltimore). 1999;78(2):65–111.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Lower EE. Medical therapy of sarcoidosis. Semin Respir Crit Care Med. 2014;35(3):391–406. DOI:10.1055/s-0034-1376401
   PubMed Web of Science ®Google Scholar
• Baughman RP, Janovcik J, Ray M, et al. Calcium and vitamin D metabolism in sarcoidosis. Sarcoidosis Vasc Diffus lung Dis Off J WASOG /World Assoc Sarcoidosis Other Granulomatous Disord. 2013;30(2):113–120.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Grutters JC. New treatment strategies for pulmonary sarcoidosis: antimetabolites, biological drugs, and other treatment approaches. Lancet Respir Med. 2015;3(10):813–822. DOI:10.1016/S2213-2600(15)00199-X
   PubMed Web of Science ®Google Scholar
• Moller DR. Negative clinical trials in sarcoidosis: failed therapies or flawed study design? Eur Respir J. 2014;44(5):1123–1126. DOI:10.1183/09031936.00156314
   PubMed Web of Science ®Google Scholar
• Cremers JP, Drent M, Bast A, et al. Multinational evidence-based World Association of Sarcoidosis and Other Granulomatous Disorders recommendations for the use of methotrexate in sarcoidosis: integrating systematic literature research and expert opinion of sarcoidologists worldwide. Curr Opin Pulm Med. 2013;19(5):545–561. DOI:10.1097/MCP.0b013e3283642a7a
   PubMed Web of Science ®Google Scholar
• Goljan-Geremek A, Bednarek M, Franczuk M, et al. Methotrexate as a single agent for treating pulmonary sarcoidosis: a single centre real-life prospective study. Pneumonol Alergol Pol. 2014;82(6):518–533. DOI:10.5603/PiAP.2014.0069
   PubMedGoogle Scholar
• Isshiki T, Yamaguchi T, Yamada Y, et al. Usefulness of low-dose methotrexate monotherapy for treating sarcoidosis. Intern Med. 2013;52(24):2727–2732.
   PubMed Web of Science ®Google Scholar
• Vorselaars ADM, Wuyts WA, Vorselaars VMM, et al. Methotrexate vs azathioprine in second-line therapy of sarcoidosis. Chest. 2013;144(3):805–812. DOI:10.1378/chest.12-1728
   PubMed Web of Science ®Google Scholar
• Vucinic VM. What is the future of methotrexate in sarcoidosis? A study and review. Curr Opin Pulm Med. 2002;8(5):470–476.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Winget DB, Lower EE. Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial. Sarcoidosis Vasc Diffus lung Dis Off J WASOG /World Assoc Sarcoidosis Other Granulomatous Disord. 2000;17(1):60–66.
   PubMed Web of Science ®Google Scholar
• Gedalia A, Molina JF, Ellis GSJ, et al. Low-dose methotrexate therapy for childhood sarcoidosis. J Pediatr. 1997;130(1):25–29.
   PubMed Web of Science ®Google Scholar
• Pia G, Pascalis L, Aresu G, et al. Evaluation of the efficacy and toxicity of the cyclosporine A-flucortolone-methotrexate combination in the treatment of sarcoidosis. Sarcoidosis Vasc Diffus lung Dis Off J WASOG /World Assoc Sarcoidosis Other Granulomatous Disord. 1996;13(2):146–152.
   PubMed Web of Science ®Google Scholar
• Lower EE, Baughman RP. Prolonged use of methotrexate for sarcoidosis. Arch Intern Med. 1995;155(8):846–851.
   PubMedGoogle Scholar
• Lower EE, Baughman RP. The use of low dose methotrexate in refractory sarcoidosis. Am J Med Sci. 1990;299(3):153–157.
   PubMed Web of Science ®Google Scholar
• Kaye O, Palazzo E, Grossin M, et al. Low-dose methotrexate: an effective corticosteroid-sparing agent in the musculoskeletal manifestations of sarcoidosis. Br J Rheumatol. 1995;34(7):642–644.
   PubMedGoogle Scholar
• Beegle SH, Barba K, Gobunsuy R, et al. Current and emerging pharmacological treatments for sarcoidosis: a review. Drug Des Devel Ther. 2013;7:325–338. DOI:10.2147/DDDT.S31064
   PubMed Web of Science ®Google Scholar
• Muller-Quernheim J, Kienast K, Held M, et al. Treatment of chronic sarcoidosis with an azathioprine/prednisolone regimen. Eur Respir J. 1999;14(5):1117–1122.
   PubMed Web of Science ®Google Scholar
• Lewis SJ, Ainslie GM, Bateman ED. Efficacy of azathioprine as second-line treatment in pulmonary sarcoidosis. Sarcoidosis Vasc Diffus lung Dis Off J WASOG /World Assoc Sarcoidosis Other Granulomatous Disord. 1999;16(1):87–92.
   PubMed Web of Science ®Google Scholar
• Sahoo DH, Bandyopadhyay D, Xu M, et al. Effectiveness and safety of leflunomide for pulmonary and extrapulmonary sarcoidosis. Eur Respir J. 2011;38(5):1145–1150. DOI:10.1183/09031936.00195010
   PubMed Web of Science ®Google Scholar
• Baughman RP, Lower EE. Leflunomide for chronic sarcoidosis. Sarcoidosis Vasc Diffus lung Dis Off J WASOG /World Assoc Sarcoidosis Other Granulomatous Disord. 2004;21(1):43–48.
   PubMed Web of Science ®Google Scholar
• Hamzeh N, Voelker A, Forssen A, et al. Efficacy of mycophenolate mofetil in sarcoidosis. Respir Med. 2014;108(11):1663–1669. DOI:10.1016/j.rmed.2014.09.013
   PubMed Web of Science ®Google Scholar
• Brill A-K, Ott SR, Geiser T. Effect and safety of mycophenolate mofetil in chronic pulmonary sarcoidosis: a retrospective study. Respiration. 2013;86(5):376–383. DOI:10.1159/000345596
   PubMed Web of Science ®Google Scholar
• Androdias G, Maillet D, Marignier R, et al. Mycophenolate mofetil may be effective in CNS sarcoidosis but not in sarcoid myopathy. Neurology. 2011;76(13):1168–1172. DOI:10.1212/WNL.0b013e318212aafb
   PubMed Web of Science ®Google Scholar
• Bhat P, Cervantes-Castaneda RA, Doctor PP, et al. Mycophenolate mofetil therapy for sarcoidosis-associated uveitis. Ocul Immunol Inflamm. 2009;17(3):185–190. DOI:10.1080/09273940902862992
   PubMed Web of Science ®Google Scholar
• Doty JD, Mazur JE, Judson MA. Treatment of corticosteroid-resistant neurosarcoidosis with a short-course cyclophosphamide regimen. Chest. 2003;124(5):2023–2026.
   PubMed Web of Science ®Google Scholar
• Wyser CP, Van Schalkwyk EM, Alheit B, et al. Treatment of progressive pulmonary sarcoidosis with cyclosporin A. A randomized controlled trial. Am J Respir Crit Care Med. 1997;156(5):1371–1376. DOI:10.1164/ajrccm.156.5.9506031
   PubMed Web of Science ®Google Scholar
• Stern BJ, Schonfeld SA, Sewell C, et al. The treatment of neurosarcoidosis with cyclosporine. Arch Neurol. 1992;49(10):1065–1072.
   PubMedGoogle Scholar
• Korsten P, Strohmayer K, Baughman RP, et al. Refractory pulmonary sarcoidosis - proposal of a definition and recommendations for the diagnostic and therapeutic approach. Clin Pulm Med. 2016;23(2):67–75. DOI:10.1097/CPM.0000000000000136
   PubMedGoogle Scholar
• Chapelon-Abric C, Saadoun D, Biard L, et al. Long-term outcome of infliximab in severe chronic and refractory systemic sarcoidosis: a report of 16 cases. Clin Exp Rheumatol. 2015;33(4):509–515.
   PubMed Web of Science ®Google Scholar
• Vorselaars ADM, Crommelin HA, Deneer VHM, et al. Effectiveness of infliximab in refractory FDG PET-positive sarcoidosis. Eur Respir J. 2015;46(1):175–185. DOI:10.1183/09031936.00227014
   PubMed Web of Science ®Google Scholar
• Vorselaars ADM, Verwoerd A, van Moorsel CHM, et al. Prediction of relapse after discontinuation of infliximab therapy in severe sarcoidosis. Eur Respir J. 2014;43(2):602–609. DOI:10.1183/09031936.00055213
   PubMed Web of Science ®Google Scholar
• Russell E, Luk F, Manocha S, et al. Long term follow-up of infliximab efficacy in pulmonary and extra-pulmonary sarcoidosis refractory to conventional therapy. Semin Arthritis Rheum. 2013;43(1):119–124. DOI:10.1016/j.semarthrit.2012.10.008
   PubMed Web of Science ®Google Scholar
• Sene T, Juillard C, Rybojad M, et al. Infliximab as a steroid-sparing agent in refractory cutaneous sarcoidosis: single-center retrospective study of 9 patients. J Am Acad Dermatol. 2012;66(2):328–332. DOI:10.1016/j.jaad.2011.05.040
   PubMed Web of Science ®Google Scholar
• Hostettler KE, Studler U, Tamm M, et al. Long-term treatment with infliximab in patients with sarcoidosis. Respiration. 2012;83(3):218–224. DOI:10.1159/000328738
   PubMed Web of Science ®Google Scholar
• Jounieaux F, Chapelon C, Valeyre D, et al. [Infliximab treatment for chronic sarcoidosis–a case series]. Rev Mal Respir. 2010;27(7):685–692. DOI:10.1016/j.rmr.2010.06.011
   PubMed Web of Science ®Google Scholar
• Baughman RP, Drent M, Kavuru M, et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med. 2006;174(7):795–802. DOI:10.1164/rccm.200603-402OC
   PubMed Web of Science ®Google Scholar
• Rossman MD, Newman LS, Baughman RP, et al. A double-blinded, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis. Sarcoidosis Vasc Diffus lung Dis Off J WASOG /World Assoc Sarcoidosis Other Granulomatous Disord. 2006;23(3):201–208.
   PubMed Web of Science ®Google Scholar
• Saleh S, Ghodsian S, Yakimova V, et al. Effectiveness of infliximab in treating selected patients with sarcoidosis. Respir Med. 2006;100(11):2053–2059. DOI:10.1016/j.rmed.2006.02.017
   PubMed Web of Science ®Google Scholar
• Doty JD, Mazur JE, Judson MA. Treatment of sarcoidosis with infliximab. Chest. 2005;127(3):1064–1071. DOI:10.1378/chest.127.3.1064
   PubMed Web of Science ®Google Scholar
• Baughman RP, Bradley DA, Lower EE. Infliximab in chronic ocular inflammation. Int J Clin Pharmacol Ther. 2005;43(1):7–11.
   PubMed Web of Science ®Google Scholar
• Pritchard C, Nadarajah K. Tumour necrosis factor alpha inhibitor treatment for sarcoidosis refractory to conventional treatments: a report of five patients. Ann Rheum Dis. 2004;63(3):318–320.
   PubMed Web of Science ®Google Scholar
• Riancho-Zarrabeitia L, Calvo-Río V, Blanco R, et al. Anti-TNF-α therapy in refractory uveitis associated with sarcoidosis: multicenter study of 17 patients. Semin Arthritis Rheum. 2015;45(3):361–368. DOI:10.1016/j.semarthrit.2015.05.010
   PubMed Web of Science ®Google Scholar
• Wijnen PA, Cremers JP, Nelemans PJ, et al. Association of the TNF-α G-308A polymorphism with TNF-inhibitor response in sarcoidosis. Eur Respir J. 2014;43(6):1730–1739. DOI:10.1183/09031936.00169413
   PubMed Web of Science ®Google Scholar
• Maneiro JR, Salgado E, Gomez-Reino JJ, et al. Efficacy and safety of TNF antagonists in sarcoidosis: data from the Spanish registry of biologics BIOBADASER and a systematic review. Semin Arthritis Rheum. 2012;42(1):89–103. DOI:10.1016/j.semarthrit.2011.12.006
   PubMed Web of Science ®Google Scholar
• Aguiar M, Marçal N, Mendes AC, et al. Infliximab for treating sarcoidosis patients, Portuguese experience. Rev Port Pneumol. 2011;17(2):85–93.
   PubMed Web of Science ®Google Scholar
• Panselinas E, Rodgers JK, Judson MA. Clinical outcomes in sarcoidosis after cessation of infliximab treatment. Respirology. 2009;14(4):522–528. DOI:10.1111/j.1440-1843.2009.01518.x
   PubMed Web of Science ®Google Scholar
• Baughman RP, Judson MA, Lower EE, et al. Infliximab for chronic cutaneous sarcoidosis: a subset analysis from a double-blind randomized clinical trial. Sarcoidosis Vasc Diffus lung Dis Off J WASOG /World Assoc Sarcoidosis Other Granulomatous Disord. 2015;32(4):289–295.
   Web of Science ®Google Scholar
• Judson MA, Baughman RP, Costabel U, et al. Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial. Eur Respir J. 2008;31(6):1189–1196. DOI:10.1183/09031936.00051907
   PubMed Web of Science ®Google Scholar
• Judson MA, Baughman RP, Costabel U, et al. The potential additional benefit of infliximab in patients with chronic pulmonary sarcoidosis already receiving corticosteroids: a retrospective analysis from a randomized clinical trial. Respir Med. 2014;108(1):189–194. DOI:10.1016/j.rmed.2013.11.019
   PubMed Web of Science ®Google Scholar
• Sweiss NJ, Barnathan ES, Lo K, et al. C-reactive protein predicts response to infliximab in patients with chronic sarcoidosis. Sarcoidosis Vasc Diffus lung Dis Off J WASOG /World Assoc Sarcoidosis Other Granulomatous Disord. 2010;27(1):49–56.
   PubMed Web of Science ®Google Scholar
• Erckens RJ, Mostard RLM, Wijnen PAHM, et al. Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis. Graefes Arch Clin Exp Ophthalmol. 2012;250(5):713–720. DOI:10.1007/s00417-011-1844-0
   PubMed Web of Science ®Google Scholar
• Pariser RJ, Paul J, Hirano S, et al. A double-blind, randomized, placebo-controlled trial of adalimumab in the treatment of cutaneous sarcoidosis. J Am Acad Dermatol. 2013;68(5):765–773. DOI:10.1016/j.jaad.2012.10.056
   PubMed Web of Science ®Google Scholar
• Crommelin HA, Van Der Burg LM, Vorselaars ADM, et al. Efficacy of adalimumab in sarcoidosis patients who developed intolerance to infliximab. Respir Med. 2016;115:72–77. DOI:10.1016/j.rmed.2016.04.011
   PubMed Web of Science ®Google Scholar
• Sweiss NJ, Noth I, Mirsaeidi M, et al. Efficacy results of a 52-week trial of adalimumab in the treatment of refractory sarcoidosis. Sarcoidosis Vasc Diffus lung Dis Off J WASOG /World Assoc Sarcoidosis Other Granulomatous Disord. 2014;31(1):46–54.
   PubMed Web of Science ®Google Scholar
• Wijnen PA, Nelemans PJ, Verschakelen JA, et al. The role of tumor necrosis factor alpha G-308A polymorphisms in the course of pulmonary sarcoidosis. Tissue Antigens. 2010;75(3):262–268. DOI:10.1111/j.1399-0039.2009.01437.x
   PubMedGoogle Scholar
• Utz JP, Limper AH, Kalra S, et al. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest. 2003;124(1):177–185.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Lower EE, Bradley DA, et al. Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial. Chest. 2005;128(2):1047–1062. DOI:10.1378/chest.128.2.1062
   PubMed Web of Science ®Google Scholar
• Perez-Alvarez R, Pérez-de-Lis M, Ramos-Casals M. Biologics-induced autoimmune diseases. Curr Opin Rheumatol. 2012;25(1):1. DOI:10.1097/BOR.0b013e32835b1366
   Web of Science ®Google Scholar
• Judson MA, Baughman RP, Costabel U, et al. Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis. Eur Respir J. 2014;44(5):1296–1307. DOI:10.1183/09031936.00000914
   PubMed Web of Science ®Google Scholar
• Sweiss NJ, Lower EE, Mirsaeidi M, et al. Rituximab in the treatment of refractory pulmonary sarcoidosis. Eur Respir J. 2014;43(5):1525–1528. DOI:10.1183/09031936.00224513
   PubMed Web of Science ®Google Scholar
• Krause ML, Cooper LT, Chareonthaitawee P, et al. Successful use of rituximab in refractory cardiac sarcoidosis. Rheumatology (Oxford). 2016;55(1):189–191. DOI:10.1093/rheumatology/kev309
   PubMed Web of Science ®Google Scholar
• Lower EE, Baughman RP, Kaufman AH. Rituximab for refractory granulomatous eye disease. Clin Ophthalmol. 2012;6:1613–1618. DOI:10.2147/OPTH.S35521
   PubMedGoogle Scholar
• Saketkoo LA, Baughman RP. Biologic therapies in the treatment of sarcoidosis. Expert Rev Clin Immunol. 2016;12(8):817–825. DOI:10.1080/1744666X.2016.1175301
   PubMed Web of Science ®Google Scholar
• Birnie DH, Sauer WH, Judson MA. Consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart. 2016;102(6):411–414. DOI:10.1136/heartjnl-2015-308708
   PubMed Web of Science ®Google Scholar
• Hamzeh NY, Wamboldt FS, Weinberger HD. Management of cardiac sarcoidosis in the United States: a Delphi study. Chest. 2012;141(1):154–162. DOI:10.1378/chest.11-0263
   PubMed Web of Science ®Google Scholar
• Drent M, Cremers JP, Jansen TL, et al. Practical eminence and experience-based recommendations for use of TNF-alpha inhibitors in sarcoidosis. Sarcoidosis Vasc Diffus lung Dis Off J WASOG /World Assoc Sarcoidosis Other Granulomatous Disord. 2014;31(2):91–107.
   PubMed Web of Science ®Google Scholar
• Lateef O, Shakoor N, Balk RA. Methotrexate pulmonary toxicity. Expert Opin Drug Saf. 2005;4(4):723–730. DOI:10.1517/14740338.4.4.723
   PubMedGoogle Scholar
• Raj R, Nugent K. Leflunomide-induced interstitial lung disease (a systematic review). Sarcoidosis Vasc Diffus lung Dis Off J WASOG /World Assoc Sarcoidosis Other Granulomatous Disord. 2013;30(3):167–176.
   PubMed Web of Science ®Google Scholar
• Vallet H, Seve P, Biard L, et al. Infliximab versus adalimumab in the treatment of refractory inflammatory uveitis: a multicenter study from the French Uveitis Network. Arthritis Rheumatol (Hoboken, NJ). 2016;68(6):1522–1530. DOI:10.1002/art.39667
   PubMed Web of Science ®Google Scholar
• Milman N, Andersen CB, Baslund B, et al. Does tumour necrosis factor-α inhibitor infliximab induce histological resolution of pulmonary sarcoid granulomas? Clin Respir J. 2007;1(2):106–113. DOI:10.1111/j.1752-699X.2007.00023.x
   PubMed Web of Science ®Google Scholar
• Keijsers RGM, Verzijlbergen JF, Van Diepen DM, et al. 18F-FDG PET in sarcoidosis: an observational study in 12 patients treated with infliximab. Sarcoidosis Vasc Diffus lung Dis Off J WASOG /World Assoc Sarcoidosis Other Granulomatous Disord. 2008;25(2):143–149.
   PubMed Web of Science ®Google Scholar
• Vorselaars ADM, Hijdra D, van Moorsel CHM, et al. Antinuclear antibodies do not predict anti-infliximab antibody induction in sarcoidosis. J Am Acad Dermatol. 2013;69(2):312–314. DOI:10.1016/j.jaad.2012.08.048
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Soto MJ, Cuadrado MJ, et al. Rituximab in systemic lupus erythematosus: a systematic review of off-label use in 188 cases. Lupus. 2009;18(9):767–776. DOI:10.1177/0961203309106174
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Brito-Zerón P, Sisó-Almirall A, et al. Topical and systemic medications for the treatment of primary Sjögren’s syndrome. Nat Rev Rheumatol. 2012;8(7):399–411. DOI:10.1038/nrrheum.2012.53
   PubMed Web of Science ®Google Scholar
• Navarra SV, Guzman RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet (London, England). 2011;377(9767):721–731. DOI:10.1016/S0140-6736(10)61354-2
   PubMed Web of Science ®Google Scholar
• Judson MA, Costabel U, Drent M, et al. The WASOG Sarcoidosis Organ Assessment Instrument: an update of a previous clinical tool. Sarcoidosis Vasc Diffus lung Dis Off J WASOG /World Assoc Sarcoidosis Other Granulomatous Disord. 2014;31(1):19–27.
   PubMed Web of Science ®Google Scholar
• Park MK, Jr F, Babaali H, et al. Steroid-sparing effects of pentoxifylline in pulmonary sarcoidosis. Sarcoidosis Vasc Diffus lung Dis Off J WASOG /World Assoc Sarcoidosis Other Granulomatous Disord. 2009;26(2):121–131.
   PubMed Web of Science ®Google Scholar
• Heij L, Niesters M, Swartjes M, et al. Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study. Mol Med. 2012;18:1430–1436. DOI:10.2119/molmed.2012.00332
   PubMed Web of Science ®Google Scholar
• Cuadrado M-J, Sciascia S, Bosch X, et al. Is it time for biosimilars in autoimmune diseases? Autoimmun Rev. 2013;12(10):954–957. DOI:10.1016/j.autrev.2013.02.005
   PubMed Web of Science ®Google Scholar
• Yoo DH, Prodanovic N, Jaworski J, et al. Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study. Ann Rheum Dis. 2016 Apr. DOI:10.1136/annrheumdis-2015-208786
   Web of Science ®Google Scholar
• Isaacs JD, Cutolo M, Keystone EC, et al. Biosimilars in immune-mediated inflammatory diseases: initial lessons from the first approved biosimilar anti-tumour necrosis factor monoclonal antibody. J Intern Med. 2016;279(1):41–59. DOI:10.1111/joim.12432
   PubMed Web of Science ®Google Scholar
• Veltkamp M, Drent M, Baughman RP. Infliximab or biosimilars in sarcoidosis; to switch or not to switch? Sarcoidosis Vasc Diffus lung Dis Off J WASOG /World Assoc Sarcoidosis Other Granulomatous Disord. 2015;32(4):280–283.
   Web of Science ®Google Scholar